FSL-1 TFA 是细菌衍生的一种 Toll 样受体 2/6 (TLR2/6) 激动剂，可增强对 HSV-2 感染的抵抗力。FSL-1 TFA 通过 TLR2 和 NF-κB/AP-1 信号通路诱导 MMP-9 产生。
| 生物活性 |
FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection[1]. FSL-1 TFA induces MMP-9 production through TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells[2].
|
| IC50 Target[1][2] |
|
体外研究
(In Vitro) |
FSL-1 significantly reduces HSV-2 replication in human vaginal epithelial cells (EC)[1].
FSL-1 induces significant resistance to experimental genital HSV-2 infection through elaboration of a specific cytokine response profile[1].
FSL-1 (50 ng/mL, 24 hours) induces MMP-9 expression at both mRNA and protein levels in human monocytic THP-1 cells[2].
FSL-1 activates the MAP kinase/NF-κB signaling pathway[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay[1]
| Cell Line: |
V11I, V12I or V19I immortalized human vaginal EC |
| Concentration: |
6 μg or 0.1 μg |
| Incubation Time: |
Added at 24, 6 or just prior to HSV-2 inoculation (104pfu/well) |
| Result: |
The 6 μg does produced significant reductions when delivered at 24 or 6 h prior to HSV-2 inoculation. The 0.1 μg dose produced reduced HSV-2 replication at 24 or 6 h prior to viral challenge. |
|
体内研究
(In Vivo) |
FSL-1 application significantly protectes against genital HSV-2 challenge in mice[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: |
Female Swiss-Webster mice (weighing 20-25 g)[1] |
| Dosage: |
2 or 6 μg |
| Administration: |
Delivered vaginally using a positive displacement pipet, prior to or following viral challenge as specified for each experiment. |
| Result: |
The 2 μg does delivered 6 h prior to HSV-2 challenge increased the ID50 (260 pfu) and LD50 (660 pfu) by 10-fold compared to DPBS vehicle control.
The single 6 μg dose produced significantly improved outcomes compared to DPBS vehicle application. |
|
| 分子量 |
|
| Formula |
|
| Sequence Shortening |
S-(2, 3-Bispalmitoyloxypropyl)-CGDPKHPKSF
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Sealed storage, away from moisture and light
| Powder |
-80deg;C |
2 years |
|
-20deg;C |
1 year |
*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture and light)
|
| Solvent Solubility |
In Vitro:;
H2O
Peptide Solubility and Storage Guidelines:
1.;;Calculate the length of the peptide.
2.;;Calculate the overall charge of the entire peptide according to the following table:
| ; |
Contents |
Assign value |
| Acidic amino acid |
Asp (D), Glu (E), and the C-terminal -COOH. |
-1 |
| Basic amino acid |
Arg (R), Lys (K), His (H), and the N-terminal -NH2 |
+1 |
| Neutral amino acid |
Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) |
0 |
3.;;Recommended solution:
| Overall charge of peptide |
Details |
| Negative (lt;0) |
1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide. |
| Positive (gt;0) |
1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO. |
| Zero (=0) |
1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration. |
|
| 参考文献 |
-
[1]. William A Rose 2nd, et al. FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection. Virol J. 2009 Nov 10;6:195.
[2]. Cathryn J Kurkjian,et al. The Toll-Like Receptor 2/6 Agonist, FSL-1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome. Sci Rep. 2017 Dec 11;7(1):17355.
|
